StockIQ.techModerna Inc. (MRNA) Stock Analysis
Free AI-powered analysis and research for Moderna Inc. stock
Sector: Healthcare
MRNA snapshot
Data as of 3 Nov 2026 close. Updated daily.
Moderna Inc. scores 57/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 90% of its 52-week range, up 828.1% over the past year. Latest reported figures show a profit margin of -141.4%, return on equity of -39.0% and revenue growth of +2.1%.
What is driving the score
- Strong Uptrend: +12
- MACD Bearish: -8
- Unprofitable (-141.4%): -15
- Low Debt (0.19 D/E): +8
- Strong Liquidity (2.29 Current Ratio): +8
- Negative ROE (-39.0%): -10
- High P/B (13.08): -5
- Strong Long-term Uptrend: +8
- Very Strong Rise (+828.1% over 1 year): +12
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full MRNA report
Moderna Inc. (MRNA) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze MRNA Now →📰 Latest Update
Buy Moderna Stock Before Q3 Earnings? Here's What to Know
Mon, November 2, 2026 at 4:14 PM UTC 2 min read
Moderna (MRNA) is set to report its Q3 2026 earnings on November 6, with sales estimated at $888.8 million and a projected loss of $1.37 per share, indicating a decline from the previous year. The article notes that Moderna's Earnings ESP is -71.32% and it holds a Zacks Rank #3, suggesting limited chances for an earnings beat. While the company has seen significant stock growth this year, its premium valuation and ongoing losses raise concerns about its near-term profitability and the commercial potential of its newer products.